| 2024-11-20 | -0.6 % |
|
| 2024-11-19 | +2.52 % |
|
| 2024-11-18 | +1.03 % |
|
| 2024-11-15 | -3.9 % |
|
| 2024-11-12 | -1.34 % |
|
| 2024-11-11 | +10.49 % |
|
| 2024-11-08 | -1.04 % |
|
| 2024-11-07 | -1.03 % |
|
| 2024-11-05 | +0.9 % |
|
| 2024-11-04 | +2.08 % |
|
| 2024-10-31 | +5.91 % |
|
| 2024-10-30 | +0.3 % |
- Bristol Myers Squibb (BMY) stock experienced a 0.3% increase, likely due to positive investor sentiment or developments in its collaborations, particularly with companies such as Exscientia, which is involved in innovative drug development targeting high unmet medical needs.
- Bristol-Myers Squibb (BMY) stock rose 0.3% due to increased institutional investment, positive analyst reports raising price targets, and the announcement of a quarterly dividend.
- Bristol-Myers Squibb (BMY) stock rose 0.3% as institutional investors, despite some reducing their positions, showed continued interest, with new acquisitions made by others, alongside positive analyst ratings and a solid dividend announcement.
- Bristol-Myers Squibb (BMY) stock rose 0.3% last night amid a consensus "Reduce" recommendation from analysts, with factors such as active buying from hedge funds and upcoming dividends contributing to the stock's uptick.
|
| 2024-10-29 | -0.27 % |
|
| 2024-10-28 | +1.39 % |
|
| 2024-10-25 | -1.89 % |
|
| 2024-10-24 | -0.26 % |
|
| 2024-10-23 | +0.57 % |
|
| 2024-10-22 | +1.23 % |
|
| 2024-10-21 | -2.07 % |
|
| 2024-10-17 | -0.36 % |
|
| 2024-10-16 | +1.16 % |
|
| 2024-10-15 | +0.17 % |
|
| 2024-10-14 | +0.9 % |
|
| 2024-10-11 | -0.38 % |
|
| 2024-10-10 | -0.76 % |
|
| 2024-10-09 | +0.61 % |
|
| 2024-10-08 | -1.8 % |
|
| 2024-10-07 | -0.96 % |
|
| 2024-10-03 | +0.82 % |
|
| 2024-10-02 | +1.63 % |
|
| 2024-10-01 | +2.24 % |
|
| 2024-09-30 | +1.63 % |
|
| 2024-09-27 | +1.58 % |
- Bristol Myers Squibb (BMY) stock increased by 1.58% following the FDA's approval of its innovative schizophrenia treatment, Cobenfy, marking a significant advancement in therapies for the condition. The stock rose due to the expected impact of the new drug, which represents a fundamentally different treatment approach and addresses a significant need in the market for effective schizophrenia therapies.
- Bristol Myers Squibb (BMY) stock rose by 1.58% following the FDA's approval of its new schizophrenia drug, which is expected to have fewer side effects than existing treatments.
- Bristol Myers Squibb (BMY) stock rose 1.58% following the FDA's approval of its new schizophrenia treatment, Cobenfy, which introduces a novel pharmacological approach and has significant potential for changing the treatment landscape for the estimated 2.8 million affected individuals in the U.S.
The stock went up due to the positive market reaction to the FDA approval of Cobenfy, which is seen as a major advancement in schizophrenia treatment and may enhance Bristol Myers Squibb's revenue prospects.
- Bristol Myers Squibb's stock rose 1.58% following the FDA's approval of their new schizophrenia drug, Cobenfy, which represents a significant advancement in treatment options for the disorder and is projected to generate substantial sales.
- Bristol Myers Squibb's (BMY) stock rose by 6% following the FDA's approval of its schizophrenia drug, which offers patients a treatment option that alleviates symptoms without common side effects.
|
| 2024-09-26 | +0.34 % |
|
| 2024-09-25 | -1.94 % |
|
| 2024-09-24 | +1.86 % |
|
| 2024-09-16 | +1.75 % |
|
| 2024-09-12 | -0.72 % |
|
| 2024-09-10 | +1.61 % |
|
| 2024-09-09 | -0.41 % |
|
| 2024-09-05 | -0.32 % |
|
| 2024-09-03 | +1.14 % |
|
| 2024-08-14 | -1.32 % |
|
| 2024-08-12 | +0.73 % |
|
| 2024-08-09 | -0.28 % |
|
| 2024-08-08 | +0.75 % |
|
| 2024-08-05 | -2.42 % |
|
| 2024-08-01 | +1.28 % |
|
| 2024-07-31 | -3.04 % |
|
| 2024-07-25 | +1.37 % |
|
| 2024-07-23 | +0.73 % |
|
| 2024-07-22 | +0.07 % |
|
| 2024-07-17 | +4.73 % |
|
| 2024-07-12 | -0.71 % |
|
| 2024-07-09 | +2.18 % |
|
| 2024-07-05 | -1 % |
|
| 2024-07-03 | -0.96 % |
|
| 2024-06-28 | +0.05 % |
|
| 2024-06-26 | +0.73 % |
- The article discusses Bristol Myers Squibb's stock (BMY), which is currently trading at $42 per share, a significant decrease from its pre-inflation shock high of $80 in June 2022 due to declining revenues from increased biosimilar competition and slashed guidance for 2024 owing to the impact of acquisitions; however, the stock showed a 0.73% increase last night, potentially due to market factors alleviating recession fears, with potential for more gains once these fears are alleviated.
- Bristol Myers Squibb (BMY) stock was up by 0.73% last night. The stock might have risen due to various factors such as positive company news, strong financial performance, market conditions, or investor sentiment.
- The article discusses the recent developments around Prothena Corporation (PRTA) and its potential impact on the stock market, as well as the licensing agreement with Bristol Myers Squibb (BMY) for the investigational drug PRX019 for neurodegenerative diseases, leading to positive expectations and analyst ratings, which could have contributed to the slight increase in Bristol Myers Squibb (BMY) stock.
|
| 2024-06-24 | +0.72 % |
|
| 2024-06-20 | +0.56 % |
|
| 2024-06-18 | -0.39 % |
|
| 2024-06-17 | -0.56 % |
|
| 2024-06-13 | -2.19 % |
|
| 2024-06-12 | -0.38 % |
|
| 2024-06-11 | +1.06 % |
|
| 2024-06-10 | +2.63 % |
|
| 2024-06-07 | +1.47 % |
|
| 2024-06-06 | -0.87 % |
|
| 2024-06-05 | -1.22 % |
|
| 2024-06-04 | -0.05 % |
|
| 2024-06-03 | +1.65 % |
|
| 2024-05-31 | +2.09 % |
- The article provides information about Bristol-Myers Squibb (BMY) stock, which was up 2.09% last night, and discusses its ratings, price targets, and recent financial performance. The stock went up likely due to favorable analyst ratings and earnings results exceeding expectations, with a positive return on equity and revenue growth reported in the last quarter.
- The article discusses the recent resignation of Dr. Roger Aston from Immuron Limited and the appointment of Dr. Jeannie Joughin as a Non-Executive Director, highlighting the company's progress in scientific endeavors and strategic partnerships, leading to positive changes and commercial success. The rise in Bristol Myers Squibb (BMY) stock could be attributed to the appointment of Dr. Joughin, who brings valuable experience from her roles with prominent companies like Bristol Myers Squibb, indicating potential positive developments for Immuron and bolstering investor confidence.
- The recent 2.09% increase in Bristol Myers Squibb (BMY) stock is attributed to the FDA approval of their Breyanzi therapy for relapsed or refractory mantle cell lymphoma, expanding the company's CAR T cell therapy portfolio.
|
| 2024-05-30 | |
- The article discusses how the U.S. Food and Drug Administration expanded the use of Bristol Myers Squibb's cell therapy, Breyanzi, for a rare type of blood cancer, but despite this positive news, the Bristol Myers Squibb (BMY) stock went down by 0.0% last night. The reason for the stock going down is not explicitly mentioned in the article.
- The article discusses how Bristol Myers Squibb (BMY) stock was down 0.0% on a particular day, mentioning the importance of dividends for investors and the historical significance of dividends in providing returns in the stock market. The stock price decline could be due to various factors affecting the company's profitability and market conditions at that given time.
- The article announces that Bristol Myers Squibb's stock (BMY) was down by 0.0% last night, and the reason behind this decline could potentially be a lack of market response to the FDA approval of Breyanzi, a CD19-directed CAR T cell therapy, for treating mantle cell lymphoma (MCL), a rare and aggressive type of non-Hodgkin lymphoma, even though the therapy demonstrated positive results in clinical trials with high response rates and a consistent safety profile.
|
| 2024-05-29 | -0.59 % |
|
| 2024-05-28 | -1.82 % |
|
| 2024-05-23 | -1.89 % |
|
| 2024-05-22 | +0.17 % |
|
| 2024-05-21 | -2.51 % |
- The article discusses Halozyme Therapeutics, Inc. announcing that Bristol Myers Squibb has been given an updated action date from the U.S. Food and Drug Administration for their Biologics License Application for the subcutaneous formulation of Opdivo, which may lead to the first subcutaneously administered PD-1 inhibitor, potentially causing Bristol Myers Squibb stock to go down due to uncertainties surrounding the approval and commercialization of this new formulation.
- The article discusses Halozyme Therapeutics' update on the FDA goal date for reviewing the BLA of a subcutaneous formulation of Opdivo co-formulated with ENHANZE technology, impacting Bristol Myers Squibb stock, which may have gone down due to the potential delay in FDA approval for the new treatment.
- Summary: Bristol Myers Squibb (BMY) stock experienced a decrease of -2.51% last night, while the company announced the launch of a national campaign called Live Your PosSCZible, aimed at empowering patients and care partners in the schizophrenia community to navigate care effectively through resources and support.
Reason for the stock decrease: The decrease in Bristol Myers Squibb (BMY) stock could potentially be due to various factors impacting the stock market such as overall market trends, changes in investor sentiment, company performance, industry news, economic indicators, or specific events related to the company itself.
|
